Quris Earns Frost & Sullivan 2022 Europe Know-how Innovation Management Award for AI-Powered Drug Security Prediction

Analysts discovered that the Quris Bio-AI Medical Prediction Platform enhances drug growth course of agility, shortens discovery timelines, will increase drug security, and improves drug pipeline diversification alternatives

SAN ANTONIO, Aug. 31, 2022 /CNW/ — Frost & Sullivan just lately researched the unreal intelligence (AI)-enabled drug security prediction know-how business and, primarily based on its findings, acknowledges Quris with the 2022 Europe Know-how Innovation Management Award. The revolutionary Quris Bio-AI Medical Prediction Platform is the primary AI breakthrough to shut the scientific prediction hole by successfully predicting which drug candidates will work safely in people.

Quris Applied sciences Ltd

Get entry to extra particulars on the award multi-media web page – https://best-practices.frost.com/quris-technologies/

“Quris AI Chip-on-Chip platform, in contrast to different AI-pharma options specializing in drug discovery, higher signifies which drug candidates will safely work in people. It makes use of AI to foretell a drug’s security, and therefore its capability to succeed, significantly in Part 1 trials, thus avoiding the excessive prices of failed scientific trials for pharmaceutical corporations,” stated Supriya Lala Kundu, a Finest Practices Analysis analyst at Frost & Sullivan.

The corporate’s platform scales to suit the intricacies of scientific prediction, requiring machine studying (ML)  fashions to routinely run an enormous variety of organic Sufferers-on-a-Chip experiments for AI coaching. Quris’s AI Chip-on-Chip know-how leverages a patented course of to check 1000’s of identified protected and unsafe medication on 1000’s of miniaturized Sufferers-on-a-Chip making use of an automatic, high-throughput system. Equally, next-generation nano-sensors allow steady response monitoring from every miniaturized organ to those medication. Furthermore, steady knowledge technology additional trains the ML classification algorithm, making it extremely predictive of scientific security and enabling it to raised discern the toxicity degree of latest drug candidates throughout testing. The revolutionary and ground-breaking platform simulates a pure human physique’s response to novel molecules with out counting on inaccurate animal testing – decreasing animal cruelty throughout pre-clinical experimentation as a consequence of its potential to restrict dependence on animal testing.

Ashish Kaul, an business analyst for Frost & Sullivan, stated, “In contrast to different organ-chip gadgets with restricted capability to run hundreds of thousands of experiments, the Quris platform is very scalable, enabling huge experiments to run cost-effectively and prepare the AI, thereby revolutionizing the pharmaceutical business. Moreover, the platform can scale as much as 1,000 medication throughout all therapeutics, notably oncology, uncommon illness, and the blood-brain barrier.”

Quris stands out from rivals primarily based on its dedication to innovation and creativity whereas attaining industrial success. Along with its drug security prediction pharma providers, Quris additionally has a drug pipeline and supplies customized medication providers. The corporate has a group of scientists, know-how consultants, medical pioneers, and seasoned administration professionals with a observe document of seamless execution. Its sturdy mental property portfolio protects its pioneering know-how, including worth relative to its development potential, thus securing a aggressive benefit. Its first AI-based Fragile-X drug is making ready for scientific testing later in 2022. Moreover, the corporate has established stem cell facilities worldwide to offer customized medication providers, additional validating its platform and enabling it to develop by way of strategic partnerships with business and analysis institutes.

“Recognition by the Frost & Sullivan group additional validates our mission to utterly rethink drug growth and resolve the largest drug discovery problem of our period – utilizing AI scientific prediction to take away longstanding obstacles for all the pharma business. Permitting the environment friendly discovery of latest medication and the repurposing/personalization of present medication, Quris will assist pharma corporations keep away from the great dangers and prices of failed scientific trials and finish the reliance on ineffective animal testing,” added Quris Founder and CEO Isaac Bentwich.

Annually, Frost & Sullivan presents this award to the corporate that develops a product with revolutionary options and performance that’s gaining fast acceptance out there. The award acknowledges the standard of the answer and the client worth enhancements it allows.

Frost & Sullivan Finest Practices awards acknowledge corporations in numerous regional and international markets for demonstrating excellent achievement and superior efficiency in management, technological innovation, customer support, and strategic product growth. Trade analysts examine market contributors and measure efficiency by way of in-depth interviews, analyses, and in depth secondary analysis to determine greatest practices within the business.

About Frost & Sullivan

For six a long time, Frost & Sullivan has been world-renowned in serving to buyers, company leaders, and governments navigate financial adjustments and determine disruptive applied sciences, Mega Traits, new enterprise fashions, and corporations to motion, leading to a steady move of development alternatives to drive future success. Contact us: Begin the dialogue.


Kristen Moore
E: kirsten.moore@frost.com

About Quris
Quris, the world’s first Bio-AI clinical-prediction platform ensures the protection and efficacy of latest medication. Revolutionizing the drug growth course of, the corporate is pioneering scientific trials on chips – testing 1000’s of novel drug candidates on lots of of miniaturized “patients-on-a-chip”. Its totally automated, self-training AI platform precisely predicts scientific security and efficacy for novel medication quicker and extra cheaply than ever earlier than – all whereas minimizing animal testing. Twin-headquartered in Boston and Israel and backed by strategic biotech and large knowledge buyers, Quris is led by a confirmed group of AI and medical analysis powerhouses who’re already making ready its lead discovery for scientific trials. For extra data, go to www.quris.ai.


Erica Camilo
P: 1.610.639.5644
E: erica@connexacommunications.com



View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/quris-earns-frost–sullivan-2022-europe-technology-innovation-leadership-award-for-ai-powered-drug-safety-prediction-301614267.html

SOURCE Frost & Sullivan



View unique content material to obtain multimedia: http://www.newswire.ca/en/releases/archive/August2022/31/c0470.html

Supply hyperlink